NasdaqGS - Delayed Quote • USD
bluebird bio, Inc. (BLUE)
At close: April 23 at 4:00 PM EDT
After hours: April 23 at 7:43 PM EDT
Earnings Estimate
| CURRENCY IN USD | Current Qtr. (Dec 2023) | Next Qtr. (Mar 2024) | Current Year (2023) | Next Year (2024) |
|---|---|---|---|---|
| No. of Analysts | 11 | 10 | 13 | 13 |
| Avg. Estimate | -0.64 | -0.44 | -1.76 | -1.61 |
| Low Estimate | -0.98 | -0.69 | -2.26 | -2.86 |
| High Estimate | -0.45 | -0.29 | -1.27 | -0.95 |
| Year Ago EPS | 0.38 | 0.21 | -3.39 | -1.76 |
Revenue Estimate
| CURRENCY IN USD | Current Qtr. (Dec 2023) | Next Qtr. (Mar 2024) | Current Year (2023) | Next Year (2024) |
|---|---|---|---|---|
| No. of Analysts | 11 | 9 | 13 | 14 |
| Avg. Estimate | 10.16M | 19.55M | 35.3M | 122.03M |
| Low Estimate | 7.7M | 12.76M | 29M | 78M |
| High Estimate | 17.3M | 30M | 49M | 167.5M |
| Year Ago Sales | 62k | 2.38M | 3.6M | 35.3M |
| Sales Growth (year/est) | 16,287.10% | 721.10% | 881.40% | 245.70% |
Earnings History
| CURRENCY IN USD | 12/31/2022 | 3/31/2023 | 6/30/2023 | 9/30/2023 |
|---|---|---|---|---|
| EPS Est. | -0.44 | -0.37 | -0.72 | -0.67 |
| EPS Actual | 0.38 | 0.21 | -0.67 | -0.66 |
| Difference | 0.82 | 0.58 | 0.05 | 0.01 |
| Surprise % | 186.40% | 156.80% | 6.90% | 1.50% |
EPS Trend
| CURRENCY IN USD | Current Qtr. (Dec 2023) | Next Qtr. (Mar 2024) | Current Year (2023) | Next Year (2024) |
|---|---|---|---|---|
| Current Estimate | -0.64 | -0.44 | -1.76 | -1.61 |
| 7 Days Ago | -0.64 | -0.44 | -1.76 | -1.61 |
| 30 Days Ago | -0.66 | -0.53 | -1.73 | -1.85 |
| 60 Days Ago | -0.66 | -0.5 | -1.84 | -1.77 |
| 90 Days Ago | -0.65 | -0.51 | -1.84 | -1.77 |
EPS Revisions
| CURRENCY IN USD | Current Qtr. (Dec 2023) | Next Qtr. (Mar 2024) | Current Year (2023) | Next Year (2024) |
|---|---|---|---|---|
| Up Last 7 Days | -- | -- | -- | -- |
| Up Last 30 Days | 3 | 5 | 3 | 6 |
| Down Last 7 Days | -- | -- | -- | -- |
| Down Last 30 Days | -- | -- | -- | -- |
Growth Estimates
| CURRENCY IN USD | BLUE | Industry | Sector | S&P 500 |
|---|---|---|---|---|
| Current Qtr. | -268.40% | -- | -- | 0.40% |
| Next Qtr. | -309.50% | -- | -- | 9.90% |
| Current Year | 48.10% | -- | -- | 4.30% |
| Next Year | 8.50% | -- | -- | 13.40% |
| Next 5 Years (per annum) | 45.80% | -- | -- | 11.09% |
| Past 5 Years (per annum) | -- | -- | -- | -- |
Research Analysis
Upgrades & Downgrades
| Reiterates | RBC Capital: Sector Perform to Sector Perform | 3/27/2024 |
| Maintains | Wells Fargo: Equal-Weight to Equal-Weight | 3/27/2024 |
| Maintains | Wedbush: Neutral to Neutral | 3/19/2024 |
| Maintains | HSBC: Reduce to Reduce | 3/5/2024 |
| Maintains | B of A Securities: Buy to Buy | 12/21/2023 |
| Maintains | Wells Fargo: Equal-Weight to Equal-Weight | 12/15/2023 |
Related Tickers
TSVT 2seventy bio, Inc.
4.6300
-0.43%
CRSP CRISPR Therapeutics AG
56.41
+1.35%
NVAX Novavax, Inc.
4.1900
+2.95%
SAGE Sage Therapeutics, Inc.
12.95
+0.47%
EDIT Editas Medicine, Inc.
5.46
-2.50%
NTLA Intellia Therapeutics, Inc.
21.53
-1.37%
IOVA Iovance Biotherapeutics, Inc.
11.86
+4.77%
IBRX ImmunityBio, Inc.
5.49
+11.13%
CRBU Caribou Biosciences, Inc.
3.9800
-0.25%
VNDA Vanda Pharmaceuticals Inc.
4.6300
-3.54%